TenX Keane's Shareholders Approve Merger With Citius Oncology Unit
TenX Keane Acquisition's (TENK) shareholders have approved the company's proposed merger with Citius Pharmaceuticals' (CTXR) wholly-owned oncology unit, the companies said Monday.
Under the terms, TenX will acquire Citius' oncology unit, while Citius Pharmaceuticals will own roughly 90% interest in the new company upon closing, and will contribute up to $10 million in cash to Citius Oncology, according to the companies.
The newly combined public entity will continue to trade on Nasdaq and will be renamed as Citius Oncology, the companies said.
The deal, unanimously approved by the boards of TenX, Citius Pharmaceuticals, and its oncology unit, was first announced in October, while the firms expect to close the merger in the coming weeks.
Shares of TenX Keane rose 35% in recent Monday premarket activity, while Citius' stock fell 12%.
Price: 16.67, Change: +4.36, Percent Change: +35.42
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。